DHR vs MS: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Morgan Stanley β fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Danaher Corporation Β· Healthcare
$195.98
+7.9% upside to fair value
Grade B
High Quality
VS
Morgan Stanley Β· Financial Services
$218.37
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
MS has more upside to fair value
(+45.0%).
MS trades at a lower forward P/E
(23.6x).
These are model outputs β not personalized investment advice.
See all research β
Valuation & Fundamentals
| Metric |
DHR |
MS |
| Current Price |
$195.98 |
$218.37 |
| Fair Value Estimate |
$211.54 |
$316.64 |
| Upside to Fair Value |
+7.9%
|
+45.0%
|
| Market Cap |
$138.7B |
$344.4B |
| Forward P/E |
37.8x
|
23.6x
|
| EV / EBITDA |
22.8x
|
9.8x
|
| Price / Sales |
5.6x
|
2.7x
|
| Price / FCF |
26.2x
|
-327.4x
|
| Revenue Growth YoY |
+3.7%
|
+22.4%
|
| Gross Margin |
60.7%
|
56.6%
|
| Operating Margin |
21.0%
|
28.4%
|
| Return on Equity |
7.1%
|
23.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.81%
|
β
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in theβ¦
Morgan Stanley is a leading global financial services firm specializing in capital markets, wealth management, and investment banking. The company demonstrates high business quality with a strong return on equity of 23.4% and robust revenue growth of 22.4% in the most recent quarter, alongside impressive earnings growth of 57.7% in the same period. Its gross margin of 56.6% and net margin of 20.2β¦
Accumulation Zones
| Metric |
DHR |
MS |
| Zone Low |
$158.66 |
$237.48 |
| Zone High |
$179.81 |
$269.14 |
| In Buy Zone? |
No
|
Yes
|